GRACE :: Breast Cancer

hormone therapy

Dr West

Breast Cancer in Older Women: Surgery and Adjuvant Therapy, by Dr. Hy Muss

Share

Dr. Hy Muss, breast cancer expert with a special expertise in treatment of older patients with cancer, continues his presentation on breast cancer in older women with a discussion of the evolution of surgery recommendations in breast cancer, along with a wonderful discussion of how he approaches the benefit vs. risk discussion for post-operative (adjuvant) therapy.  I found myself thinking that his explanation was so helpful that I’d want to incorporate elements of his presentation into my own discussions of the complex issues around adjuvant therapy.

Here are the video and audio versions of the program, along with the associated transcript and figures.

Muss BC in Older Women Pt 3 Surgery and Adjuvant Rx Audio Podcast

Muss BC in Older Women Pt 3 Surgery and Adjuvant Rx Transcript

Muss BC in Older Women Pt 3 Surgery and Adjuvant Rx Figures

Continue reading


New Targeted Therapy approved for ER-positive, HER2-negative Breast Cancer: Afinitor with Aromasin

Share

On July 20, 2012, the U.S. Food and Drug Administration (FDA) gave us another option for treating postmenopausal patients with metastatic, ER-positive, HER2-negative breast cancer whose disease has progressed on Arimidex or Femara by approving Afinitor (everolimus) in combination with Aromasin (exemestane). This new approval was based on the BOLERO-2 trial which was a randomized, double-blind, multicenter trial conducted in 724 postmenopausal women.  Patients were randomized to receive either Afinitor 10 mg/day plus Aromasin 25 mg/day or to placebo plus Aromasin 25 mg/day. Both Aromasin and Afinitor are oral drugs.

Aromasin is an aromatase inhibitor which works by lowering estrogen levels in postmenopausal women. This trial was based on the observation that resistance (either not responding or stopping responding) to hormonal therapy is associated with a tumor being able to use pathways other than the estrogen pathway to survive and grow. One example of this is activation of the mammalian target of rapamycin (mTOR) signaling pathway in cells. Afinitor targets the mTOR pathway and is classified as an mTOR inhibitor. 

On the BOLERO-2 trial, the median progression-free survival (PFS) was longer for the patients receiving Afinitor (7.8 vs 3.2 months). These results were consistent regardless of age, race, presence or extent of visceral metastases (such as liver metastases), and response to prior hormonal therapy.  The response rate was also better for the patients receiving Afinitor (12.6% vs 1.7%).  The analysis of overall survival (OS) was not significant however this was an interim analysis.  The final OS analysis isn’t expected to become available until June, 2014.

Continue reading


Ask Us, Q&A
Breast Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243